Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 18, 2025PharmaceuticalsOpen Access

PROTACs and Glues: Striking Perspectives for Engineering Cancer Therapy À La Carte

View Full Paper
Ask AI
Bookmark
Share

Authors

JFJean-Marc FerreroJGJocelyn GalBMBaharia Mograbi

Discussion

Loading...

Member takes

Overview

Research reveals that PROTACs and molecular glues promote selective degradation of proteins, suggesting transformative potential for cancer therapy.

Key Points

  • PROTACs and molecular glues enable the targeted degradation of hard-to-drug proteins in cancer treatments.
  • These approaches leverage the ubiquitin-proteasome system for effective therapeutic strategies against tumors.
  • AI-based strategies can enhance the design and discovery of selective protein binders, expediting the development of treatments.
  • The integration of these methods in molecular tumor boards could significantly advance personalized oncology and patient care.

Cite This Study

Ferrero et al. (2025) studied this question.

synapsesocial.com/papers/68d433aa713b0b5dfea730cbhttps://doi.org/10.3390/ph18091397
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities2025
  2. 2Recent Advances in Targeted Protein Degradation Molecular Glues as Anticancer Drugs2025 · 6 citations
  3. 3Nanotechnology-Based Strategies for Overcoming Clinical Limitations of PROTACs in Cancer Therapy2025
  4. 4Recent Advances in Nanomedicine: Cutting-Edge Research on Nano-PROTAC Delivery Systems for Cancer Therapy2025
  5. 5Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions2025